II. Mechanism
- Nucleoside Reverse Transcriptase Inhibitor (nRTI)
- Inhibits HIV replication
III. Pharmacokinetics
- Well absorbed with 83% Bioavailability
IV. Efficacy
V. Dosing
- Stavudine 40 mg PO bid ($224/month)
VI. Toxicity
- Less Bone Marrow toxicity than Zidovudine (AZT)
VII. Adverse Effects
- See nRTI for adverse effects attributed to the class
- Headache
- Nausea, Vomiting
- Asthenia, confusion
- Serum Aminotransferase elevation
- Creatine Kinase elevation
- Lipodystrophy
- Hyperlipidemia
- Glucose intollerance to Diabetes Mellitus
-
Lactic Acidosis
- Potentially lethal
- Higher risk when used in combination with Didanosine
- Moderate painful sensory Peripheral Neuropathy
- Most common serious side effect (more than other nRTI agents)
- Dose related (may not recur if restart at lower dose)
- Pancreatitis and hyperamylasemia (rare)